Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.

Fenaclon is an anticonvulsant. It was developed in the former USSR. It is indicated for the treatment of epilepsy.

Isamoltan (CGP 361A) is a β-adrenoceptor and serotonin 1B receptor antagonist. Isamoltane has reported activity as an anxiolytic in man. Isamoltan had been in phase III clinical trials for the treatment of anxiety. However, this research has been discontinued.

Lotrafiban (SmithKline Beecham) is a member of the latest generation of orally-active platelet GPIIb/IIIa blockers undergoing Phase III clinical trials to test the relative effectiveness versus other oral platelet inhibitors for ischaemic conditions including unstable angina, restenosis after PCI and stroke. Lotrafiban is converted from an esterified prodrug by plasma and liver esterases to a peptidomimetic of the arginine-glycine-aspartic acid amino acid sequence. This sequence itself mimics the binding site of fibrinogen and von Willebrand Factor to the platelet GPIIb/IIIa receptor. Preliminary results of the clinical trial APLAUD (antiplatelet useful dose) show that lotrafiban is clinically safe and well-tolerated in patients with recent myocardial infarction, unstable angina, transient ischaemic attack (TIA), or stroke when added to aspirin therapy. The Blockade of the IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial of SmithKline Beecham's oral GpIIb/IIIa blocker, lotrafiban, has been stopped early because of concerns about both safety and efficacy. The drug was showing a higher mortality rate than placebo, and was also associated with an increased incidence of serious thrombocytopenia and major bleeding. As a result of these findings the company has discontinued development of lotrafiban.

Diclofensine is an antidepressant with equipotent inhibitive effects on the neuronal uptake of norepinephrine (NE), serotonin, and dopamine. It is devoid of monoamine-releasing or monoaminoxidase-inhibiting properties. Diclofensine was found to be an effective antidepressant in human trials, with relatively few side effects, but was ultimately dropped from clinical development.

Dexsotalol is an isomer of antiarrhythmic drug d,l-sotalol, but in opposite to drug, it increases the incidence of arrhythmias

Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.

Etifenin is a diagnostic radiopharmaceutical for the liver function assessment. It is used for hepatobiliary function scintigraphy where there is the following suspicion: Acute cholecystitis; Chronic gall duct changes; Occlusion of ductus choledochus; Congenital aberrances of the gall duct system such as atresia; Provision of evidence of bile leak; For differential diagnosis of intrahepatic growth (suspicion of focal nodular hyperplasia versus suspicion of liver cell cancer). The diagnostic significance in liver cancer is rather marginal compared to other imaging procedures. No information on adverse reactions after intravenous injection of the ready-to-use solution is available.

Etifenin is a diagnostic radiopharmaceutical for the liver function assessment. It is used for hepatobiliary function scintigraphy where there is the following suspicion: Acute cholecystitis; Chronic gall duct changes; Occlusion of ductus choledochus; Congenital aberrances of the gall duct system such as atresia; Provision of evidence of bile leak; For differential diagnosis of intrahepatic growth (suspicion of focal nodular hyperplasia versus suspicion of liver cell cancer). The diagnostic significance in liver cancer is rather marginal compared to other imaging procedures. No information on adverse reactions after intravenous injection of the ready-to-use solution is available.

Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.